- Home
- ARVN
ARVN
Arvinas Inc.
as 11-14-2025 3:43pm EST
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 676.2M | IPO Year: | 2018 |
| Target Price: | $17.80 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.90 - $27.00 | Next Earning Date: | 11-05-2025 |
| Revenue: | $312,300,000 | Revenue Growth: | 93.86% |
| Revenue Growth (this year): | -1.45% | Revenue Growth (next year): | -61.22% |
Stock Insider Trading Activity of Arvinas Inc. (ARVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Loomis David K | ARVN | Chief Accounting Officer | Nov 7 '25 | Sell | $9.89 | 230 | $2,274.70 | 31,697 | |
| Morrison Briggs | ARVN | Director | Sep 22 '25 | Buy | $7.57 | 30,000 | $227,010.00 | 76,021 |
Latest Arvinas Inc. News
ARVN Breaking Stock News: Dive into ARVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
MT Newswires
a month ago
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
GlobeNewswire
a month ago
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Zacks
5 months ago
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
MT Newswires
5 months ago
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma
GlobeNewswire
5 months ago
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
MT Newswires
5 months ago
Sector Update: Health Care Stocks Advance Premarket Friday
MT Newswires
5 months ago
Arvinas, Pfizer Submit New Drug Application for Vepdegestrant as Breast Cancer Treatment
Compare ARVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARVN Arvinas Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.